Market capitalization | $295.34b |
Enterprise Value | $351.31b |
PER (TTM) P/E ratio | 49.80 |
EV/FCF (TTM) EV/FCF | 16.08 |
EV/Sales (TTM) EV/Sales | 6.46 |
P/S ratio (TTM) P/S ratio | 5.43 |
P/B ratio (TTM) P/B ratio | 36.88 |
Dividend yield | 3.58% |
Last dividend (FY23) | $5.99 |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
29 Analysts have issued a AbbVie forecast:
29 Analysts have issued a AbbVie forecast:
Mar '24 |
+/-
%
|
||
Revenue | 54,403 54,403 |
4%
4%
|
|
Gross Profit | 37,533 37,533 |
8%
8%
|
|
EBITDA | 25,974 25,974 |
18%
18%
|
EBIT (Operating Income) EBIT | 17,338 17,338 |
26%
26%
|
Net Profit | 5,950 5,950 |
21%
21%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Head office | United States |
CEO | Robert Michael |
Employees | 50,000 |
Founded | 2011 |
Website | www.abbvie.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.